At Akamis Bio, we are unwearying in pursuit of our mission to positively impact the lives of people living with cancer.
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by our lead clinical stage program, NG-350A. We have an extensive and growing body of clinical experience with T-SIGn® therapeutics with more than 200 patients treated across both the monotherapy setting, as well as in combination with checkpoint inhibitors. Across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.
T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery.
We have a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Our clinical studies are investigating the use of T-SIGn® therapeutics in the monotherapy setting, as well as in combination with other immuno-oncology agents to target specific solid tumor immune resistance mechanisms.